Combination of dasatinib plus Nivolumab - CML
Important notice: You must inform your CML doctor or a qualified doctor before using this drug. The material presented here is for information purposes only; it is not a substitute for your physician’s guidance and care.
Nivolumab to control molecular response in chronic myeloid leukemia
September 2018, Leukemia Research
CA180-373 = A Phase 1B Study with Dasatinib plus Nivolumab in CML
November 1, 2017, CML Advocates Network
An open-label, phase 1b, dose-escalation study (CA180-373) of dasatinib plus nivolumab, an investigational anti-programmed cell death 1 (PD-1) antibody, in patients (pts) with previously treated chronic myeloid leukemia (CML).
2014, Journal Of Clinical Oncology